The LSDs panel can screen six diseases including Fabry disease, Gaucher’s disease, MPS I, Niemann-Pick disease (Type A and Type B) and Pompe disease.

PerkinElmer Diagnostics president Jim Corbett said LSDs panel has the ability to detect six additional genetic disorders within 72 hours of specimen receipt, enabling earlier clinical intervention for better neonatal health.

"While the primary goal is to provide information that improves a newborn’s quality of life and a definitive diagnosis for parents, such tests also have the potential to lower palliative healthcare costs for families and insurers, due to early diagnosis," Corbett said.